The timing of low dose naltrexone (LDN) administration, specifically in the evening hours, is a common practice in clinical settings. The rationale behind this approach centers on the drug’s mechanism of action and its interaction with the body’s natural circadian rhythms. Naltrexone, at low doses, is believed to briefly block opioid receptors. This temporary blockade stimulates the body to produce more endorphins, the naturally occurring pain relievers and mood regulators. This increased endorphin production is thought to be most effective when it aligns with the body’s natural sleep-wake cycle.
Administering LDN before sleep allows the receptor blockade and subsequent endorphin surge to occur during the early morning hours, a time when endorphin levels are typically low. This strategy aims to optimize the body’s natural pain management and immune regulation processes. Furthermore, taking it at night may minimize potential side effects that some individuals experience when starting LDN, such as initial anxiety or sleep disturbances. Historically, the use of LDN at night developed through clinical observations and anecdotal evidence suggesting improved patient outcomes and tolerability.
